Proactive intravitreal aflibercept dosing provides functional improvements in nAMD

The 24-month results from a multicenter, observational, prospective study demonstrate that in routine clinical practice a proactive intravitreal aflibercept (IVT-AFL) regimen achieves functional improvements in patients with treatment-naïve neovascular age-related macular degeneration (nAMD). The proportion of patients achieving ≥ 70 letters at 24 months increased, and patients with baseline best corrected visual acuity (BCVA) of ≥70 letters maintained vision regardless of the followed IVT-AFL label.

The XTEND study included 1,466 participants from 17 countries, with study eyes receiving IVT-AFL injection. The mean changes in BCVA and central subfield thickness (CST) from baseline to month 12 and month 24 were measured and stratified by baseline factors. Treatment exposure and safety data were evaluated.

For the overall population, the mean standard deviation (SD) age was 78.7 ± 8.5 years, and 891 patients (60.8%) were female. The mean SD baseline BCVA was 54.3 ± 20.3 letters and CST was 374 ± 126 µm. At month 12 and month 24, mean BCVA change was +4.3 and + 2.3, respectively. Mean CST was – 106 μm and – 109 μm at month 12 and month 24, respectively. At 2 years, 41.5% of patients had a BCVA ≥ 70 letters. Patients received a mean SD of 7.7 ± 2.7 injections by month 12 and 10.8 ± 5.0 injections by month 24 (3.1 injections between M12 and M24). Adverse events were consistent with the known IVT-AFL safety profile.

Reference
Korobelnik JF, Chaudhary V, Mitchell P, et al. XTEND: two-year results from a global observational study investigating proactive dosing of intravitreal aflibercept in neovascular age-related macular degeneration. Ophthalmol Ther. January 10, 2024. doi: 10.1007/s40123-023-00867-x